Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
Globe Newswire•21/10/2026•08:30 ET
0
Key Highlights
- ➤Sotagliflozin improved cardiac structure and function in a hypertrophic cardiomyopathy mouse model
- ➤Sotagliflozin reduced platelet activation and thrombus formation in human blood and animal models
- ➤Empagliflozin did not show sotagliflozin’s inhibitory effects on platelet activity and thrombosis
- ➤SONATA-HCM Phase 3 topline results expected in the first quarter of 2027
Expert Statements
Craig Granowitz, Senior vice president and chief medical officer of Lexicon Pharmaceuticals
“These studies add to a growing body of evidence demonstrating the broad biological effects of sotagliflozin across multiple pathways relevant to cardiovascular disease”
Craig Granowitz, Senior vice president and chief medical officer of Lexicon Pharmaceuticals
“From cardiac remodeling and mitochondrial function to platelet activation and thrombosis, the findings continue to expand our understanding of the differentiated biology associated with dual SGLT1 and SGLT2 inhibition and further support the scientific rationale for evaluating sotagliflozin in areas of significant unmet need, including hypertrophic cardiomyopathy.”
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy --
-- Second preclinical study shows inhibitory effects of sotagliflozin on platelet activity and thrombus formation --
Get started
Create a free account to read the full story.